Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients

Microorganisms

Udo Holtick¹  Christoph Scheid¹  Patrick Affeldt²  Franziska Grundmann²  Christine E. Kurschat²  Roman-Ulrich Müller²  Martin Kann²  Dirk Stippel³  Moritz Trappe⁴  Maike Wirtz⁴  Rolf Kaiser⁴  Elena Knops⁴  Veronica Di Cristanziano⁴  Eva Heger⁴ 

[1] Department I of Internal Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany;Department II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany;Department of General, Visceral, Cancer and Transplant Surgery, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany;Institute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Fürst-Pückler Straße 56, 50935 Cologne, Germany;

关键词: CMV;    ELISPOT;    drug resistance;    kidney;    bone marrow;    transplantation;   

DOI  :  10.3390/microorganisms9081666

来源: DOAJ

【 摘 要 】

The treatment options for cytomegalovirus (CMV) infections in immunosuppressed patients are limited, mainly consisting of (val-)ganciclovir (VGC/GCV) as the first-line treatment. We report on three transplant recipients, one stem cell transplant (allo-HSCT) patient and two kidney transplant (KTx) recipients, with prolonged CMV viremia treated with a combined therapy based on letermovir (LMV), CMV-specific intravenous immunoglobulins (IVIg), and VGC/GCV, which led to the sustained control of CMV viremia in all patients.

【 授权许可】

Unknown